AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26907482 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PPI (120 mg pantoprazole)
Number of subjects: 166
Study 25315828 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline 1000 mg
Number of subjects: 24
Study 25315828 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline 500 mg
Number of subjects: 24
Study 25315828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23140964 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Magna bioprosthesis
Number of subjects: 300
Study 23140964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorin Mitroflow bioprosthesis
Number of subjects: 300
Study 23140964 — intervention group
Group type: EXPERIMENTAL
Intervention: St. Jude Epic bioprosthesis
Number of subjects: 300
Study 20488328 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mononuclear cell (BM-MNC) infusion
Number of subjects: 110
Study 20488328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 17940145 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle with bioabsorbable screw fixation
Number of subjects: 77
Study 17940145 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle with bioabsorbable screw fixation
Number of subjects: 77
Study 17940145 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle with metallic screw fixation
Number of subjects: 77
Study 17940145 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 77
Study 15197206 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver function tests (LFTs) including alkaline phosphatase, AST, ALT, or bilirubin
Number of subjects: 2320
Study 15197206 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver function tests (LFTs)
Number of subjects: 2320
Study 11496617 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron given orally 45 minutes prior to induction of anaesthesia (group I)
Number of subjects: 136
Study 11496617 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron given intravenously during induction of anaesthesia (group II)
Number of subjects: 136
Study 11496617 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg DHB given intravenously during induction of anaesthesia (group III)
Number of subjects: 136
Study 11496617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group IV)
Number of subjects: 136
Study 9725117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (2.5‐5.0 mg twice per day)
Number of subjects: 80
Study 9725117 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 80
Study 9725117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine + mecamylamine
Number of subjects: 80
Study 9725117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Number of subjects: 80
Study 8050424 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory limb capnography
Number of subjects: 0
Study 8050424 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum inspired carbon dioxide at the mouth
Number of subjects: 0
Study 8050424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow:minute volume ratio
Number of subjects: 0
Study 8050424 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory limb capnography
Number of subjects: 0
Study 2731601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 14
Study 2731601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2731601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g daily for one week)
Number of subjects: 14
Study 765079 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision, curettage and primary suture under systemic antibiotic cover
Number of subjects: 219
Study 765079 — intervention group
Group type: COMPARATOR
Intervention: Deroofing and packing
Number of subjects: 219
Study 30926190 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab)2 antivenom
Number of subjects: 60
Study 30926190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28627310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-level dynamic treatment regimens
Number of subjects: 0
Study 25296928 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-Release Oral System Methylphenidate
Number of subjects: 36
Study 25296928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24072224 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 45
Study 24072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Glittre test (GT)
Number of subjects: 45
Study 24072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) scores
Number of subjects: 45
Study 24072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps and biceps strength
Number of subjects: 45
Study 24072224 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea scores
Number of subjects: 45
Study 24072224 — intervention group
Group type: EXPERIMENTAL
Intervention: GT performance
Number of subjects: 45
Study 24072224 — intervention group
Group type: EXPERIMENTAL
Intervention: GT and 6MWT correlation
Number of subjects: 45
Study 24072224 — intervention group
Group type: EXPERIMENTAL
Intervention: GT and physical functioning domain of SF-36 correlation
Number of subjects: 45
Study 21147422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise combined with routine treatment
Number of subjects: 20
Study 21147422 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment including electrotherapy and general exercises
Number of subjects: 20
Study 18348023 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic colloids (4% succinylated gelatine or 6% pentastarch)
Number of subjects: 160
Study 18348023 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions
Number of subjects: 160
Study 18348023 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 160
Study 18348023 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving synthetic colloids)
Number of subjects: 160
Study 16844888 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day training session for general practitioners (GPs) on managing patients with unexplained physical symptoms
Number of subjects: 295
Study 16844888 — intervention group
Group type: COMPARATOR
Intervention: Untrained GPs
Number of subjects: 295
Study 16844888 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day training session for general practitioners (GPs)
Number of subjects: 295
Study 12626993 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690
Study 12626993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study 11771602 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine impregnated dressing (Biopatch)
Number of subjects: 55
Study 11771602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dressing)
Number of subjects: 55
Study 9419398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary iron intake (averaged from self‐administered food frequency questionnaires, energy‐adjusted, categorized into quartiles)
Number of subjects: 0
Study 9419398 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements (limited examination)
Number of subjects: 0
Study 8306007 — intervention group
Group type: COMPARATOR
Intervention: Intensive glycemic control
Number of subjects: 529
Study 8306007 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 529
Study 2949672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 17
Study 2949672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 17
Study 29510490 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOLIGOTM IL5040 isomaltooligosaccharide
Number of subjects: 36
Study 29510490 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOLIGOTM IL7010 isomaltooligosaccharide
Number of subjects: 36
Study 29510490 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 36
Study 26846471 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg daily, 5 mg three times a day)
Number of subjects: 224
Study 26846471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no meloxicam)
Number of subjects: 224
Study 26846471 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg daily, 5 mg three times a day) in patients without viral hepatitis (NBNC-HCC)
Number of subjects: 224
Study 26846471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no meloxicam) in patients without viral hepatitis (NBNC-HCC)
Number of subjects: 224
Study 24952837 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (30 minutes, three times a week for four months)
Number of subjects: 68
Study 24952837 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 68
Study 24952837 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 23488651 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isolate protein (Group A)
Number of subjects: 60
Study 23488651 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isolate protein + resistance exercises (Group B)
Number of subjects: 60
Study 23488651 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 60
Study 20857256 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (VL group)
Number of subjects: 68
Study 20857256 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL group)
Number of subjects: 68
Study 18178947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate-based (Bic/Lac) solution
Number of subjects: 26
Study 18178947 — intervention group
Group type: COMPARATOR
Intervention: Conventional lactate-based (Lac) solution
Number of subjects: 26
Study 16189338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intrathecal morphine (6 microg x kg(‐1) per ideal body weight in 5 mL normal saline)
Number of subjects: 43
Study 16189338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intrathecal morphine
Number of subjects: 43
Study 16189338 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal normal saline (5 mL)
Number of subjects: 43
Study 16189338 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal normal saline
Number of subjects: 43
Study 12499341 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 or 1000 mg/d)
Number of subjects: 48
Study 12499341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10532104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (syrup) plus dexamethasone
Number of subjects: 52
Study 10532104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron plus dexamethasone (per os)
Number of subjects: 52
Study 8546549 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive ($5 payment)
Number of subjects: 244
Study 8546549 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health adviser (assistance by a peer)
Number of subjects: 244
Study 8546549 — intervention group
Group type: COMPARATOR
Intervention: Usual care (referral slips and bus tokens only)
Number of subjects: 244
Study 2062873 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (0.6 mg p.o.)
Number of subjects: 28
Study 2062873 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered ginger (500 mg)
Number of subjects: 28
Study 2062873 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder ginger (500 or 1,000 mg) or fresh ginger root (1,000 mg)
Number of subjects: 28
Study 2062873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2062873 — intervention group
Group type: COMPARATOR
Intervention: Gastric emptying
Number of subjects: 28
Study 3900809 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder exercises started immediately after surgery (Group A)
Number of subjects: 57
Study 3900809 — intervention group
Group type: COMPARATOR
Intervention: Shoulder exercises started on the seventh postoperative day (Group B)
Number of subjects: 57
Study 3900809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 57
Study 30219102 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus wrist orthosis (PT + O)
Number of subjects: 61
Study 30219102 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 61
Study 27093770 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7 mL of 2% mepivacaine with 1:100,000 epinephrine and 1 mL of 75 TRU/mL hyaluronidase
Number of subjects: 0
Study 27093770 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL of saline)
Number of subjects: 0
Study 24286636 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (2.67 mmol/L)
Number of subjects: 45
Study 24286636 — intervention group
Group type: COMPARATOR
Intervention: Papaverine (1.0 mmol/L)
Number of subjects: 45
Study 24286636 — intervention group
Group type: COMPARATOR
Intervention: VG (30 μmol/L each of verapamil and nitroglycerin)
Number of subjects: 45
Study 22510505 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel plus cisplatin (LP)
Number of subjects: 100
Study 22510505 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (TP)
Number of subjects: 100
Study 19626043 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 15
Study 19626043 — intervention group
Group type: COMPARATOR
Intervention: Usual diet supplemented with potassium, magnesium and fibre
Number of subjects: 15
Study 18782643 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorder symptoms in patients with bipolar disorder
Number of subjects: 81
Study 18782643 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of control over eating (LOC)
Number of subjects: 81
Study 18782643 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly LOC during the past six months
Number of subjects: 81
Study 17219172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic air (1.0 O(2)) during exercise
Number of subjects: 6
Study 17219172 — intervention group
Group type: COMPARATOR
Intervention: Normoxic air (0.21 O(2)) during exercise
Number of subjects: 6
Study 17219172 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting metabolites with oxygen supplementation
Number of subjects: 6
Study 17219172 — intervention group
Group type: COMPARATOR
Intervention: Resting metabolites without oxygen supplementation
Number of subjects: 6
Study 16083172 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Body Weight Support Treadmill Training (PBWSTT)
Number of subjects: 48
Study 16083172 — intervention group
Group type: COMPARATOR
Intervention: Floor walking training (Control)
Number of subjects: 48
Study 16083172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PBWSTT and Floor walking training)
Number of subjects: 48
Study 15700491 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg or 8 mg once daily
Number of subjects: 678
Study 15700491 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin standard 1 mg to 8 mg once daily
Number of subjects: 678
Study 9142604 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant implantable contraceptives
Number of subjects: 0
Study 9142604 — intervention group
Group type: COMPARATOR
Intervention: Licensing in industrialized countries
Number of subjects: 0
Study 8416463 — intervention group
Group type: EXPERIMENTAL
Intervention: Home management
Number of subjects: 67
Study 8416463 — intervention group
Group type: COMPARATOR
Intervention: Hospital management
Number of subjects: 67
Study 3743441 — intervention group
Group type: EXPERIMENTAL
Intervention: Isophane human insulin
Number of subjects: 0
Study 3743441 — intervention group
Group type: COMPARATOR
Intervention: Isophane pork insulin
Number of subjects: 0
Study 3743441 — intervention group
Group type: COMPARATOR
Intervention: Protamine-bound biosynthetic human insulin
Number of subjects: 0
Study 3743441 — intervention group
Group type: COMPARATOR
Intervention: Porcine preparations
Number of subjects: 0
Study 31439338 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (OAC)
Number of subjects: 1621
Study 31439338 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC with antiplatelet therapy (APT)
Number of subjects: 1621
Study 31439338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (APT) alone
Number of subjects: 1621
Study 31439338 — intervention group
Group type: COMPARATOR
Intervention: No OAC or APT
Number of subjects: 1621
Study 28634906 — intervention group
Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 302
Study 28634906 — intervention group
Group type: COMPARATOR
Intervention: EUC
Number of subjects: 302
Study 25773757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 155
Study 25773757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 24 weeks
Number of subjects: 155
Study 23892201 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5599
Study 23892201 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5599
Study 21631670 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard trabeculectomy (4 × 4 mm scleral flap)
Number of subjects: 41
Study 21631670 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtrabeculectomy (2 × 2 mm scleral flap)
Number of subjects: 41
Study 19321589 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phytate meal
Number of subjects: 34
Study 19321589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic dephytinization
Number of subjects: 34
Study 19321589 — intervention group
Group type: COMPARATOR
Intervention: Fermentation of maize porridge
Number of subjects: 34
Study 16440160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administered at 20 ng/kg per minute
Number of subjects: 0
Study 12635120 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (three sets of eight isometric contractions, three times weekly for 12 weeks)
Number of subjects: 10
Study 12635120 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 10
Study 11124694 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative apheresis with hemodilution using 4% albumin, retrieving c‐PRP and 2 units of ERC.
Number of subjects: 80
Study 11124694 — intervention group
Group type: COMPARATOR
Intervention: Preoperative autologous donation (PAD) with 2 units of ERC + plasma retrieved within 4 weeks preoperatively.
Number of subjects: 80
Study 9338422 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-ml Bioenervi treatment (125 ml contained 25 ml Bioenervi)
Number of subjects: 9
Study 9338422 — intervention group
Group type: EXPERIMENTAL
Intervention: 125-ml Bioenervi treatment (125 ml contained 125 ml Bioenervi)
Number of subjects: 9
Study 9338422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal milk whey) treatment
Number of subjects: 9
Study 9338422 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (25-ml Bioenervi, 125-ml Bioenervi, and placebo)
Number of subjects: 9
Study 8452062 — intervention group
Group type: EXPERIMENTAL
Intervention: guaifenesin
Number of subjects: 97
Study 8452062 — intervention group
Group type: EXPERIMENTAL
Intervention: guaifenesin plus codeine
Number of subjects: 97
Study 8452062 — intervention group
Group type: EXPERIMENTAL
Intervention: guaifenesin plus dextromethorphan
Number of subjects: 97
Study 3455114 — intervention group
Group type: EXPERIMENTAL
Intervention: AAFP's 'Competitive Edge' marketing package (two marketing brochures)
Number of subjects: 466
Study 3455114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no marketing brochures)
Number of subjects: 466
Study 29421993 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg Zn gluconate per day)
Number of subjects: 50
Study 29421993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltose dextrin per day)
Number of subjects: 50
Study 29030386 — intervention group
Group type: EXPERIMENTAL
Intervention: Wahakura
Number of subjects: 200
Study 29030386 — intervention group
Group type: COMPARATOR
Intervention: Bassinet
Number of subjects: 200
Study 27338747 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (Branched-Chain Amino Acids)
Number of subjects: 77
Study 27338747 — intervention group
Group type: COMPARATOR
Intervention: non-BCAA
Number of subjects: 77
Study 24102423 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program including aerobic and strengthening exercises, conducted between the 20th and 36th week of gestation.
Number of subjects: 855
Study 24102423 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (Control)
Number of subjects: 855
Study 22143109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometry and buddy support
Number of subjects: 399
Study 22143109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometry and no buddy
Number of subjects: 399
Study 22143109 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddy peer support intervention
Number of subjects: 399
Study 22143109 — intervention group
Group type: COMPARATOR
Intervention: Control groups (no pedometry and no buddy)
Number of subjects: 399
Study 20159045 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D electroanatomical mapping (Carto)
Number of subjects: 91
Study 20159045 — intervention group
Group type: COMPARATOR
Intervention: 3DATG
Number of subjects: 91
Study 20159045 — intervention group
Group type: EXPERIMENTAL
Intervention: Carto
Number of subjects: 91
Study 17284557 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive reasoning training
Number of subjects: 302
Study 17284557 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial orientation training
Number of subjects: 302
Study 17284557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reasoning ability training and increased proximal training gain
Number of subjects: 302
Study 17284557 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning ability training
Number of subjects: 302
Study 16122642 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderated e-mail discussion group
Number of subjects: 421